July 22, 2025 — HeartBeam, Inc., a medical technology company focused on transforming cardiac care by providing powerful personalized insights, recently announced it has been awarded the Innovation Award in Remote Cardiac Diagnostics as part of the 2025 Medical Device Network Excellence Awards. The award honors HeartBeam’s FDA-cleared electrocardiogram (ECG) technology that enables clinical-grade diagnostics for arrhythmia assessment outside of traditional healthcare settings, expanding access to timely and actionable cardiac care.
The Medical Device Network Excellence Awards program is one of the most respected independent recognition programs in the industry. The program analyzes over one billion datasets annually to recognize forward-thinking companies that drive positive change and set new standards for excellence across the global medical device sector.
The award recognizes HeartBeam’s proprietary 3D ECG technology which captures the heart’s electrical signals in 3 distinct, non-coplanar directions and then synthesizes these signals into a 12-lead ECG. The technology makes it possible to provide diagnostic fidelity similar to a standard 12-lead ECG in a credit card-sized, cable-free device which enables patients to record their arrhythmia symptoms the moment they occur. The 12-lead ECG synthesis software is currently under review by FDA, and upon FDA clearance, HeartBeam plans to initiate commercialization.
“This recognition affirms our vision of transforming how cardiac conditions are monitored and detected and validates our belief that access to high-fidelity ECG data should not be limited by healthcare settings,” said Robert Eno, Chief Executive Officer of HeartBeam. “As we continue to prepare for the market introduction of the HeartBeam System, this award highlights our leadership position in delivering clinically validated, patient-centric solutions to advance remote cardiac care.”
For additional information, visit HeartBeam.com.
July 24, 2025 
